GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…
Tag: 2021
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-…
Q2 Half Year Report 2021
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
– A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical…
ObsEva to Present at Upcoming Investor Conferences
GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) [i]; agent is being…
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and…
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for…
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
– Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an…
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation– – Phase 2b/3 adaptive…